<SEC-DOCUMENT>0001654954-24-006918.txt : 20240524
<SEC-HEADER>0001654954-24-006918.hdr.sgml : 20240524
<ACCEPTANCE-DATETIME>20240524165138
ACCESSION NUMBER:		0001654954-24-006918
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240524
FILED AS OF DATE:		20240524
DATE AS OF CHANGE:		20240524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FSD Pharma Inc.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39152
		FILM NUMBER:		24985231

	BUSINESS ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>fsd_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title>fsd_6k.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">Form 6-K</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO RULE 13a-16 OR 15d-16</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the month of: <strong><u>May 24, 2024</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission File Number: <strong><u>001-39152</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FSD PHARMA INC.</font></strong></p></td></tr> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(Translation of registrant&#8217;s name into English)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>199 Bay St., Suite 4000</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>Toronto, Ontario M5L 1A9, Canada</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive office)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:justify;">FSD Pharma Inc.</p> <p style="MARGIN: 0px; text-align:justify;">(Registrant)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Date: May 24, 2024</p></td> <td> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="margin:0px">/s/ Nathan Coyle</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Nathan Coyle, Chief Financial Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">2</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT INDEX</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="margin:0px"><strong>Exhibit</strong></p></td> <td style="width:2%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="margin:0px"><strong>Description</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><a href="fsd_ex991.htm">99.1</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><a href="fsd_ex991.htm">Press Release</a></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">3</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fsd_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>fsd_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="fsd_ex991img1.gif"><strong></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:14pt">FSD Pharma Provides Corporate Update</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Toronto, ON &#8211; May 24, 2024</strong> &#8211; FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (&#8220;<strong>FSD Pharma</strong>&#8221; or the &#8220;<strong>Company</strong>&#8221;), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that<strong> </strong>it has entered into an investor relations services agreement with IR Agency LLC (the &#8220;<strong>Agency</strong>&#8221;) effective May 22, 2024.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the agreement, the Agency has agreed to communicate information about the Company to the financial community including, but not limited to, creating Company profiles, media distribution and building a digital community with respect to the Company for a period of one month beginning on May 28, 2024, in exchange for a fee of C$ $335,699 (US$245,000 converted at a price of US$1.00:C$1.3674 based on the Bank of Canada exchange rate as of May 23, 2024).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Agency is arm&#8217;s-length to the Company and neither the Agency nor its principals hold an equity interest in the Company&#8217;s securities, either directly or indirectly, or the right to acquire any equity interest.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Rafael Pereira of the Agency will be involved in providing the investor relations services to the Company. The Agency&#8217;s contact information is as follows: IR Agency LLC, 23 Downing Street, Newark NJ 07105, <font style="color:blue"><u>info@ir.agency</u></font></a> (862) 210-5959</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>About IR Agency LLC</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">IR Agency doesn&#8217;t just want to build a digital community of potential investors. They&#8217;re opening your virtual doors to life&#8217;s visionaries, innovators, and pioneers &#8211; the kind of creative minds and deep-pocketed shareholders that you need on board. It&#8217;s a space for CEOs who want more &#8211; more growth, more profits, and more market share, where we do all the heavy lifting, so you can dedicate your time where it counts; building an industry powerhouse.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>About FSD Pharma</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FSD Pharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. (&#8220;<strong>Lucid</strong>&#8221;), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (&#8220;<strong>Lucid-MS</strong>&#8221;). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma has also licensed UNBUZZD&#8482;, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. (&#8220;<strong>Celly Nu</strong>&#8221;) and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD Pharma continues its R&amp;D activities to develop novel formulations for alcohol misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cautionary Note Regarding Forward-Looking Information</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>This press release contains forward-looking statements and forward-looking information (collectively, &#8220;forward-looking statements&#8221;) within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;expected&#8221;, &#8220;scheduled&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;anticipates&#8221;, &#8220;hopes&#8221;, &#8220;planned&#8221; or &#8220;believes&#8221;, or variations of such words and phrases, or states that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221;, &#8220;potentially&#8221; or &#8220;will&#8221; be taken, occur or be achieved. More particularly, and without limitation, this press release contains forward-looking statements contained in this press release include statements concerning the future of FSD Pharma and are based on certain assumptions that FSD Pharma has made in respect thereof as of the date of this press release, including those relating to the services provided by the Agency pursuant to the agreement. FSD Pharma cannot give any assurance that such forward-looking statements will prove to have been correct. </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it believes the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct and these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties including, but not limited to: the services provided by the Agency pursuant to the agreement; the fact that the drug development efforts of the Company and Lucid are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company and Lucid may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company and Lucid; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company and Lucid; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company and Lucid; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company and Lucid; and other risks. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date of this press release.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Further information regarding factors that may cause actual results to differ materially are included in the Company&#8217;s annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR+ (</em><em><u><font style="color:blue">www.sedarplus.ca</font></u></em><em>) and with the SEC on EDGAR (</em><em><u><font style="color:blue">www.sec.gov</font></u></em><em>), including the Company&#8217;s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, the Prospectus and Registration Statement, each under the heading &#8220;Risk Factors&#8221;. This list of risk factors should not be construed as exhaustive. Readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. The forward-looking statements contained in this document speak only as of the date of this document. FSD Pharma does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Contacts:</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FSD Pharma Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, FSD Pharma Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Email: Zsaeed@fsdpharma.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Telephone: (416) 854-8884</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Investor Relations</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Email: ir@fsdpharma.com, info@fsdpharma.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Website: www.fsdpharma.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>fsd_ex991img1.gif
<TEXT>
begin 644 fsd_ex991img1.gif
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !C ,0# 2(  A$! Q$!_\0
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M!QQC&!TSV!_ 5^.ZLR.&4E6!R"."#7W-^S'\?;SQ4R?#WQK>^=K$:$Z;?/\
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M@=L^O'^/'6D'P'^,)_YI[J_XQ =L^O\ D\=:"CESX[\<'.?&6N'/7_B8S?\
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MX*K'MZ,**5Q7.,HHHIC/V.T__D%VG_7%/_015JJFG +I5FJC $*8 _W15N@
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M3_$+'_(T>'<X_OS]?^_= 'RW17UQI_[$7B"20#5?'>G6J=S;6;SD<>C,G?\
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M9<L,0^0VP\@>8?-KW?PGXGTOQEX0TSQ1HDWG6&HPB:,]U[,I_P!I6!4CU!H
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B)]/OX[6-0$2>>.3SG [;RBDCIG)QDDDHI >J44450S__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
